| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 181 | Photosensitizer dye | US12125939 | 2008-05-23 | US07645879B2 | 2010-01-12 | Chun-Guey Wu; Chia-Yuan Chen; Shi-Jhang Wu; Jheng-Ying Li |
| A photosensitizer dye is provided. The photosensitizer dye is a Ru complex as formula (1): | ||||||
| 182 | Compounds for organic electronic devices | US12066554 | 2006-08-16 | US20090295275A1 | 2009-12-03 | Amir Parham; Susanne Heun; Horst Vestweber; Philipp Stoessel; Holger Heil; Rocco Fortte |
| The present invention relates to the improvement of organic electroluminescent devices, in particular blue-emitting devices, by using compounds of the formula (1) or formula (2) as dopants in the emitting layer or as hole-transport material in a hole-transport layer. | ||||||
| 183 | PHOTOSENSITIZER DYE | US12125939 | 2008-05-23 | US20090209761A1 | 2009-08-20 | Chun-Guey Wu; Chia-Yuan Chen; Shi-Jhang Wu; Jheng-Ying Li |
| A photosensitizer dye is provided. The photosensitizer dye is a Ru complex as formula (1): wherein X1 represents one of formula (2)˜(18) and X2 represents hydrogen atom or X1 and X2 both represent one of formula (2)˜(18), wherein Z1 represents one of formula (35)˜(41) and Z2 represents hydrogen atom or one of formula (35)˜(41) or a group the same with Z1. | ||||||
| 184 | Novel methods for treatment of diseases related to activated lymphocytes | US11897669 | 2007-08-31 | US20080125415A1 | 2008-05-29 | Stephen Roth; Clayton Buck; Christopher Self; Gary Olson |
| The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists. | ||||||
| 185 | Liminescent Silicon Oxide Flakes | US11631446 | 2005-07-06 | US20070221884A1 | 2007-09-27 | Holger Hoppe; Patrice Bujard; Martin Muller; Hans Reichert |
| The present invention relates to luminescent SiOz, flakes, especially porous luminescent SiOz flakes, wherein 0.70≦z≦2.0, especially 0.95≦z≦2.0, comprising an organic, or inorganic luminescent compound, or composition, which can provide enhanced (long term) luminescent efficacy. | ||||||
| 186 | Methine compound and silver halide photographic material containing the same | US10631810 | 2003-08-01 | US07161010B2 | 2007-01-09 | Katsumi Kobayashi; Takashi Katoh; Junji Nishigaki |
| Disclosed is a compound represented by the following formula (I): wherein Z1 represents an atomic group necessary to form a 5- or 6-membered nitrogen-containing heterocyclic ring; Z2 represents an atomic group necessary to form a 5- or 6-membered heterocyclic ring, Z2 may further be substituted, or may be condensed with a hetero ring of a benzene ring; R1 represents a hydrogen atom, a halogen atom, a mercapto group, an alkyl group, an alkenyl group, an aryl group, an alkylthio group, an alkenylthio group, or an arylthio group; L1 and L2 each represents a methine group; pi represents 0 or 1; V1 represents a substituent; and n represents 0, 1 or 2, and when n represents 2, a plurality of V1 may be the same or different. | ||||||
| 187 | Hair-dyeing agent | US11385790 | 2006-03-22 | US20060230547A1 | 2006-10-19 | Katsumi Kobayashi |
| A hair-dyeing agent, which contains at least one compound represented by formula (1) or (2) as a dye: wherein X1 and X2 each are an oxygen atom, nitrogen atom, sulfur atom, or dialkylmethylene group; R1, R2, R3, R4, R5, R6, R7, and R8 each independently are a hydrogen atom or substituent; M1 and M2 each are a counter ion to balance the charge of the molecule; and m1 and m2 each are a number of 0 or more necessary to neutralize the charge of the molecule. | ||||||
| 188 | Method for inhibiting polymerization of (meth)acrylic acid and its esters using an inhibitor and a process for making a compound useful as such an inhibitor | US11229916 | 2005-09-19 | US20060074257A1 | 2006-04-06 | Stephen Bass; Robert Mason; Joy Mendoza; Steven Skoog; Mark Vandersall |
| This invention relates to a method for inhibiting polymerization of (meth)acrylic acid and its esters using a polymerization inhibitor which comprises at least one reduced halide-content azine dye-based compound. A process for producing reduced halide-content azine dye-based compounds using ion exchange resin technology is also provided. | ||||||
| 189 | Method and reagent for measuring cholesterol in high density lipoproteins | US10531315 | 2003-10-16 | US20060014229A1 | 2006-01-19 | Yuki Katayama; Mayumi Fujinaka |
| A method for quantitatively determining cholesterol in high-density lipoprotein in a sample, which comprises: reacting a sample with i) cholesterol esterase and cholesterol oxidase or ii) cholesterol esterase, an oxidized coenzyme and cholesterol dehydrogenase in an aqueous medium comprising i) nonionic surfactant, polyanion and albumin or ii) a combination of a surfactant selected from the group consisting of polyoxyethylene alkylamine or polyoxyethylene alkenylamine and a surfactant selected from the group consisting of polyoxyethylene polycyclic phenyl ether sulfate and an anionic bile acid derivative, and measuring the formed hydrogen peroxide or a reduced coenzyme; and a reagent used therefor. | ||||||
| 190 | Bis-propyl amine analog and composition | US10715244 | 2003-11-17 | US20040152017A1 | 2004-08-05 | Rakesh Vig; Scott Gerger; Richard H. Selinfreund; Peter Miller; Mike Cunningham; Chris Philips; Ewell Cook; Anthony A. Saglimbeni |
| Copy-protected optical medium utilizing a composition comprising a transient optical state change security materials capable of changing optical state when exposed to a wavelength of about 630 nm to about 660 nm and an electron transfer agent. | ||||||
| 191 | Methine compound and silver halide photographic material containing the same | US09985060 | 2001-11-01 | US06667405B2 | 2003-12-23 | Katsumi Kobayashi; Takashi Katoh; Junji Nishigaki |
| Disclosed is a compound represented by the following formula (I): wherein Z1 represents an atomic group necessary to form a 5- or 6-membered nitrogen-containing heterocyclic ring; Z2 represents an atomic group necessary to form a 5- or 6-membered heterocyclic ring, Z2 may further be substituted, or may be condensed with a hetero ring or a benzene ring; R1 represents a hydrogen atom, a halogen atom, a mercapto group, an alkyl group, an alkenyl group, an aryl group, an alkylthio group, an alkenylthio group, or an arylthio group; L1 and L2 each represents a methine group; p1 represents 0 or 1; V1 represents a substituent; and n represents 0, 1 or 2, and when n represents 2, a plurality of V1 may be the same or different. | ||||||
| 192 | Process for manufacture of in vivo stain composition | US10096468 | 2002-03-11 | US20020111501A1 | 2002-08-15 | Douglas D. Burkett |
| A process for synthesizing 2-amino-5-dimethlyaminophenyl thiosulfonic acid comprises the step of oxidizing N,Nnull-dimethyl-null-phenylene-diamine in the presence of a source of thiosulfate ions, while maintaining the temperature of the reaction mixture not higher than about 10null C. This compound is useful as an intermediate in the synthesis of toluidine blue null. A process for manufacturing toluidine blue null with improved yield, includes the step of preparing the intermediate 2-amino-5-diethylaminopropyl thiosulfonic acid according to the above described procedure. | ||||||
| 193 | Nitrogen-containing tricyclic compounds and drugs containing the same | US09985416 | 2001-11-02 | US20020103189A1 | 2002-08-01 | Mitsuaki Miyamoto; Tatsuya Yoshiuchi; Keizo Sato; Makoto Kaino; Masayuki Tanaka; Motohiro Soejima; Katsuhiro Moriya; Yoshinori Sakuma; Koji Yamada; Kokichi Harada; Yukio Nishizawa; Seiichi Kobayashi; Makoto Okita; Koichi Katayama |
| A phenothiazine, acridan, acridone oxime, acridone hydrazone and dibenzodiazepine derivative represented by formula (I) 1 effective against diseases in which histamine, leukotrienes, etc. participate and effective in preventing or treating diseases in which chemical mediators such as histamine and leukotrienes participate, for example, asthma, allergic rhinitis, atopic dermatitis, urticaria, hay fever, gastrointestinal allergy and food allergy. | ||||||
| 194 | Process for preparing polymers in the presence of triazolyl radicals | US09254455 | 1999-03-10 | US06380315B1 | 2002-04-30 | Michael Fischer; Jürgen Koch; Wolfgang Paulus; Klaus Müllen; Markus Klapper; Marco Steenbock; Daniel M. Colombani |
| A process for preparing polymers which comprises conducting polymerization in the presence of free radicals of the formula I where Q is NR2 or S and T is CR3R4 or S and R1, R2, R3 and R4 can be identical or different and independently are hydrogen, C1- to C20-alkyl or C6- to C18-aryl. | ||||||
| 195 | Process for manufacture of in vivo stain composition | US75980801 | 2001-01-11 | US6372904B2 | 2002-04-16 | BURKETT DOUGLAS D |
| A process for synthesizing 2-amino-5-dimethlyaminophenyl thiosulfonic acid comprises the step of oxidizing N,N'-dimethyl-rho-phenylene-diamine in the presence of a source of thiosulfate ions, while maintaining the temperature of the reaction mixture not higher than about 10° C. This compound is useful as an intermediate in the synthesis of toluidine blue O. A process for manufacturing toluidine blue O with improved yield, includes the step of preparing the intermediate 2-amino-5-diethylaminopropyl thiosulfonic acid according to the above described procedure. | ||||||
| 196 | Nitrogen-containing tricyclic compounds and drugs containing the same | US09125451 | 1998-09-21 | US06333322B1 | 2001-12-25 | Mitsuaki Miyamoto; Tatsuya Yoshiuchi; Keizo Sato; Makoto Kaino; Masayuki Tanaka; Motohiro Soejima; Katsuhiro Moriya; Yoshinori Sakuma; Koji Yamada; Kokichi Harada; Yukio Nishizawa; Seiichi Kobayashi; Makoto Okita; Koichi Katayama |
| A phenothiazine, acridan, acridone oxime, acridone hydrazone and dibenzodiazepine derivative represented by formula (I) effective against diseases in which histamine, leukotrienes, etc. participate and effective in preventing or treating diseases in which chemical mediators such as histamine and leukotrienes participate, for example, asthma, allergic rhinitis, atopic dermatitis, urticaria, hay fever, gastrointestinal allergy and food allergy. | ||||||
| 197 | Developing agents for (photo) thermographic systems | US382899 | 1995-02-03 | US5663042A | 1997-09-02 | Duncan McL. A. Grieve; Justine A. Mooney; William E. Bottomley; John H. A. Stibbard; Andrew W. Mott; Robert J. D. Nairne; David C. Bays; Stephen S. C. Poon; Raymond J. Kenney; Gilbert L. Eian; Takuzo Ishida; Doreen C. Lynch; Roger A. Mader; Sharon M. Simpson; Kim M. Vogel |
| A thermographic element comprising in a non-aqueous binder medium a silver salt oxidizing agent in reactive association with a compound comprising a plurality of redox color releasing moieties such that oxidation of each redox color releasing moiety causes release from said compound of a thermally diffusible dye.The compounds many of which are new incorporate two or more developer moieties into a single molecule to minimize the diffusibility of the compound. Following oxidation, either directly by the silver salt or by means of a cross-oxidizing agent, each oxidized developer moiety releases a thermally diffusible dye. The compounds are of sufficient size and molecular weight to slow or prevent diffusion in imaging systems and yet possess several active developer moieties per molecule which is advantageous over known ballasted dye releasers which comprise bulky molecules with only a single developer moiety. | ||||||
| 198 | Radiation-curable ink and coating compositions containing ionic dye compounds as initiators | US77911 | 1987-07-27 | US4751102A | 1988-06-14 | Paul C. Adair; Michael J. Moore |
| The present invention provides radiation-curable ink compositions comprising pigment and a photohardenable composition; the photohardenable composition comprises a free radical addition polymerizable or crosslinkable compound and an ionic dye-reactive counter ion compound which is capable of absorbing actinic radiation and producing free radicals which initiate free radical polymerization or crosslinking of the polymerizable or crosslinkable compound. | ||||||
| 199 | Novel oxazine-ureas and thiazine urea chromophors as fluorescent labels | US753937 | 1985-07-11 | US4714763A | 1987-12-22 | Spyros Theodoropulos |
| Novel urea derivatives of oxazine and thiazine chromophors have the structural formula I or II. ##STR1## wherein M is oxygen or sulfur, R.sub.1 and R.sub.2 are aliphatic alkyl groups or hydrogen; R.sub.3 is hydrogen or alkyl group; R.sub.4 is hydrogen, alkyl or amine group; R.sub.5 is hydrogen, amine or alkyl group; X.sup..crclbar. is an anion consisting of an organic (e.g. CH.sub.3 COO.sup..crclbar., CH.sub.3 CH.sub.2 COO.sup..crclbar. and the like) or inorganic specie (e.g. Cl.sup..crclbar., Br.sup..crclbar., I.sup..crclbar., ClO.sub.4.sup..crclbar., SO.sub.4 ", and the like); n is 0 to 20; Z is N.dbd.C.dbd.O, N.dbd.C.dbd.S, carboxylic, primary or secondary amine, and when n=0, Z may be ##STR2## wherein Q is hydroxyl, amino, carboxylic, sulfydryl, isocyanato, or isothiocyanato.The functional oxazine-urea and thiazine-urea derivatives react with compounds of interest to form adducts resulting in the fluorescent labeling of the compound. | ||||||
| 200 | Phenoxazine and phenothiazine dyes and leuco forms thereof | US656460 | 1984-10-01 | US4622395A | 1986-11-11 | Peter A. Bellus; Roger A. Mader |
| Novel phenoxazine and phenothiazine dyes have the formula ##STR1## wherein X can be --S-- or --O--;each R can be the same or different and is independently selected from(1) hydrogen,(2) an unsubstituted aryl or alkyl group or these groups substituted by up to four groups selected from alkyl, alkoxy, cyano, hydroxy, halogen, nitro, mercapto, alkylsulfonyl, arylsulfonyl, and Z, where Z is as defined below, wherein all alkyl and alkoxy groups have 1 to 20 carbon atoms; and(3) Z, wherein Z can be ##STR2## wherein each Q can be the same or different and is independently selected from(1) hydrogen,(2) an unsubstituted aryl or alkyl group or these groups substituted by up to four groups selected from alkyl, alkoxy, cyano, hydroxy, halogen, nitro, mercapto, alkylsulfonyl, arylsulfonyl, and Z, where Z is as defined above, wherein all alkyl and alkoxy groups have 1 to 20 carbon atoms; andR' is the same or different and is independently selected from hydrogen, halogen, alkyl or alkoxy of 1 to 6 carbon atoms or these groups substituted by up to 3 halogen atoms; andA is an anion;with the proviso that R and L can have up to a total of 5 carbonyl and sulfonyl groups, and with the proviso that the average value of a Taft Constant and of a Hammett Constant for the two R groups on at least one 3- or 7-position nitrogen atom is greater than 1.0 for a Taft Constant and greater than +0.1 for a Hammett Constant. | ||||||
QQ群二维码
意见反馈
意见反馈